IN8bio, Inc. - INAB STOCK NEWS

IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company, announced that CEO William Ho will present at the Jefferies Global Healthcare Conference on June 8, 2022, from 1:30 to 1:55 p.m. EDT. The presentation will focus on the company's innovative gamma-delta T cell therapies and its DeltEx platform. Additional upcoming presentations include the Biotechnology Innovation Organization International Convention and the Next Generation CAR & T Cell Therapies event. IN8bio is conducting Phase 1 clinical trials for INB-200 and INB-100, targeting glioblastoma and leukemia.

IN8bio, Inc. (Nasdaq: INAB) reported promising results from its Phase 1 trial for INB-200 in glioblastoma multiforme (GBM) patients. Notably, 100% of patients exceeded the median progression-free survival (PFS), with some exceeding overall survival (OS) expectations. One patient remains stable after one year post-enrollment. The safety profile was manageable with no severe adverse events reported. Enrollment for the third cohort has begun, with further updates anticipated later in 2022.

IN8bio announced the expansion of its DeltEx gamma-delta T cell platform to include induced pluripotent stem cells (iPSCs) at the ASGCT 25th Annual Meeting. Data revealed that iPSC-derived gamma-delta T cells exhibit robust cytotoxicity and can be genetically modified with an internal CAR-T construct, marking a significant advancement in the field. IN8bio is the first to demonstrate directed differentiation of both Vdelta1 and Vdelta2 sub-types. The company plans to host a webcast on May 17, 2022, to discuss these findings and its ongoing clinical programs.

IN8bio, Inc. (Nasdaq: INAB) reported encouraging results for its Phase 1 clinical trials of INB-100 and INB-200, focusing on leukemia and glioblastoma patients. At the EBMT Annual Meeting, all three INB-100 patients were in complete remission, with durable remissions between 9 to 23 months. INB-200 showed a manageable safety profile with no dose-limiting toxicities. Financially, cash decreased to $32.1 million, and R&D expenses rose to $2.4 million. The company experienced a net loss of $6.1 million for Q1 2022, compared to a loss of $3.1 million in Q1 2021.

IN8bio, Inc. (Nasdaq: INAB) announced the launch of its new iPSC-based gamma-delta T cell platform, making it one of the few companies able to create both Vdelta1 and Vdelta2 T cell subtypes. This platform aims to facilitate the scaled manufacturing of 'off-the-shelf' cellular therapies. CEO William Ho highlighted this as a significant advancement, with plans to present data at the ASGCT Annual Meeting from May 16-19, 2022. The company is also set to discuss ongoing clinical trials and its product pipeline during a workshop on May 17, 2022.

IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical firm, announced its participation in several conferences in May 2022. Highlights include presentations at the ISCT International Society for Cell & Gene Therapy and the Allogeneic Cell Therapies Summit, featuring topics on innovative gamma-delta T cell therapies. Key speakers include CEO William Ho and COO Kate Rochlin. The company also focuses on the DeltEx platform for developing gamma-delta T cell therapies targeting solid tumors and leukemia. IN8bio is conducting Phase 1 trials for products INB-200 and INB-100.

IN8bio (Nasdaq: INAB) announced the appointment of Urvashi Patel, Ph.D., as Vice President of Regulatory Affairs and Stacey Bilinski as Vice President of Clinical Operations. These appointments aim to enhance the company's clinical pipeline, with plans to file at least one new IND this year. Dr. Patel brings over 17 years of drug development experience, including cell therapy, while Ms. Bilinski has over 30 years in clinical operations. IN8bio is focused on developing innovative gamma-delta T cell therapies for cancer treatment.

IN8bio, a clinical-stage biopharmaceutical company, announced its presentations for upcoming April conferences. At the AACR Annual Meeting 2022 in New Orleans, Dr. Lawrence Lamb will discuss γδ T cell-based therapy for gliomas on April 11, and Dr. Lei Ding will address drug-resistant immunotherapy on April 13. Additionally, CEO William Ho will participate in a panel at the BIO Alabama Annual Conference 2022 on April 25.

IN8bio specializes in developing gamma-delta T cell therapies for tumors and is currently running Phase 1 trials for INB-200 and INB-100.

IN8bio, Inc. (Nasdaq: INAB) shared promising results from its ongoing Phase 1 trial of INB-100 for treating patients with high-risk acute myeloid leukemia (AML). All three patients treated showed durable remissions lasting 23.3, 21.0, and 9.3 months post-bone marrow transplant (BMT). The immune systems of patients were effectively reconstituted at six months, with no serious treatment-related adverse events reported. This update was presented at the European Society for Blood and Marrow Transplantation (EBMT) 48th Annual Meeting, indicating potential for further clinical advancements.